Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Antibe Therapeutics Inc    ATE   CA0370251039

ANTIBE THERAPEUTICS INC

(ATE)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tsx Venture Exchange
06/20/2019 06/21/2019 06/24/2019 06/25/2019 06/26/2019 Date
0.315(c) 0.325(c) 0.32(c) 0.325(c) 0.315(c) Last
98 008 127 550 244 750 621 202 194 380 Volume
-1.56% +3.17% -1.54% +1.56% -3.08% Change
More quotes
Financials (CAD)
Sales 2019 9,30 M
EBIT 2019 -9,50 M
Net income 2019 -8,30 M
Debt 2019 -
Yield 2019 -
Sales 2020 9,84 M
EBIT 2020 -5,20 M
Net income 2020 -6,00 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 8,30x
Capi. / Sales2020 7,85x
Capitalization 77,2 M
More Financials
Company
Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and... 
Sector
Biotechnology & Medical Research
Calendar
07/02 | 09:30amShareholder meeting
More about the company
Latest news on ANTIBE THERAPEUTICS INC
04/29ANTIBE THERAPEUTICS : to Present at 2019 Bloom Burton & Co. Healthcare Investor ..
AQ
04/17ANTIBE THERAPEUTICS INC. : - Phase 2B GI Safety Results for ATB-346 Published in..
AQ
04/01ANTIBE THERAPEUTICS : Announces Commencement of Phase 2B Dose-Ranging, Efficacy ..
AQ
02/18ANTIBE THERAPEUTICS : Reports Q3 2019 Interim Financial and Operating Results
AQ
02/04ANTIBE THERAPEUTICS : IIROC Trading Resumption - ATE
AQ
02/04ANTIBE THERAPEUTICS : IIROC Trading Halt - ATE
AQ
01/22ANTIBE THERAPEUTICS : Receives Approval to Initiate Part Two of Phase 2B Dose-Ra..
AQ
2018ANTIBE THERAPEUTICS : Announces Successful Completion of Part One of Phase 2B Do..
BU
2018KWANGDONG PHARMACEUTICAL : licenses Canadian companys nonsteroidal anti-inflamma..
AQ
2018ANTIBE THERAPEUTICS : Announces Strategic Licensing Deal for Lead Drug in South ..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/26FDA Approves Sanofi, Regeneron Treatment for Chronic Rhinosinusitis with Nasa..
DJ
06/21Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
DJ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
More sector news : Bio Therapeutic Drugs
Chart ANTIBE THERAPEUTICS INC
Duration : Period :
Antibe Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 1,40  CAD
Spread / Average Target 344%
EPS Revisions
Managers
NameTitle
Daniel Legault President, Chief Executive Officer & Director
Walter M. MacNee Chairman
Alain Wilson Chief Financial Officer
John Lawrence Wallace Director & Chief Scientific Officer
Roderick J. Flower Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTIBE THERAPEUTICS INC1.61%59
GILEAD SCIENCES6.60%87 076
VERTEX PHARMACEUTICALS7.21%46 140
REGENERON PHARMACEUTICALS-18.32%33 708
GENMAB9.41%11 177
ARRAY BIOPHARMA INC223.65%10 247